CohBar Inc
NASDAQ:CWBR
Intrinsic Value
CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. [ Read More ]
The intrinsic value of one CWBR stock under the Base Case scenario is 4.2347 USD. Compared to the current market price of 0.9003 USD, CohBar Inc is Undervalued by 79%.
Valuation Backtest
CohBar Inc
Run backtest to discover the historical profit from buying and selling CWBR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CohBar Inc
Current Assets | 12.5m |
Cash & Short-Term Investments | 12.3m |
Receivables | 40k |
Other Current Assets | 120k |
Non-Current Assets | 40k |
Intangibles | 20k |
Other Non-Current Assets | 20k |
Current Liabilities | 3m |
Accounts Payable | 1.4m |
Accrued Liabilities | 1.6m |
Other Current Liabilities | -10k |
Earnings Waterfall
CohBar Inc
Revenue
|
0
USD
|
Operating Expenses
|
-13.1m
USD
|
Operating Income
|
-13.1m
USD
|
Other Expenses
|
430k
USD
|
Net Income
|
-12.7m
USD
|
Free Cash Flow Analysis
CohBar Inc
What is Free Cash Flow?
CWBR Profitability Score
Profitability Due Diligence
CohBar Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
CohBar Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
CWBR Solvency Score
Solvency Due Diligence
CohBar Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
CohBar Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CWBR Price Targets Summary
CohBar Inc
Ownership
CWBR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CWBR Price
CohBar Inc
Average Annual Return | -50.2% |
Standard Deviation of Annual Returns | 33.08% |
Max Drawdown | -99% |
Market Capitalization | 2.6m USD |
Shares Outstanding | 2 906 930 |
Percentage of Shares Shorted | 0.52% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm focuses on developing therapeutics targeting chronic and age-related diseases. The company is advancing a pipeline of peptide analogs through varying stages of development, such as CB5138-3 for idiopathic pulmonary fibrosis (IPF); CB4211 for the treatment of non-alcoholic steatohepatitis (NASH) and obesity; and several preclinical and discovery-stage programs. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing, and optimizing analogs of these natural mitochondrial derived peptides (MDPs), as well as developing and conducting screens to identify and characterize the activities of these peptides are referred to its Mito+ platform. The company is using its Mito+ platform to identify and develop modified versions of natural peptides called analogs, to treat a range of serious conditions, with a focus on chronic diseases involving inflammation and fibrosis.
Contact
IPO
Employees
Officers
The intrinsic value of one CWBR stock under the Base Case scenario is 4.2347 USD.
Compared to the current market price of 0.9003 USD, CohBar Inc is Undervalued by 79%.